ALDX - NASDAQ
Aldeyra Therapeutics, Inc.
$1.86
+0.71%Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
At a Glance
Live Snapshotaldx
Cash at Beginning of Period
Last Annual Value
54527.09B
3-Year CAGR
6091%
5-Year CAGR
1551%
10-Year CAGR
379%
Aldeyra Therapeutics, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Aldeyra Therapeutics, Inc. NASDAQ:ALDX | 54527.09B | 7127.6% | 1375.9% | 354.0% | |
 Alto Neuroscience, Inc. NYSE:ANRO | 168.73M | 51.7% | 111.3% | N/A | |
 Candel Therapeutics, Inc. NASDAQ:CADL | 102.92M | 13.5% | 23.9% | N/A | |
 Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD | 61.64M | 58.2% | N/A | N/A | |
 Editas Medicine, Inc. NASDAQ:EDIT | 135.42M | -2.3% | -1.2% | -0.6% | |
 Capricor Therapeutics, Inc. NASDAQ:CAPR | 11.29B | 955.3% | 221.9% | 114.1% | |
 Galectin Therapeutics Inc. NASDAQ:GALT | 15.12M | -6.7% | -11.0% | -5.2% | |
 Vanda Pharmaceuticals Inc. NASDAQ:VNDA | 102.78M | -8.8% | 11.0% | 7.3% | |
 Genelux Corporation NASDAQ:GNLX | 8.56M | 178.4% | -5.5% | N/A | |
21.94M | 57.9% | 6.5% | N/A | ||
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 97.17M | 36.4% | 28.7% | N/A |
Aldeyra Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your ALDX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.